TAVIRA, PORTUGAL,25th November 2024 – Gro-Vida, a medical cannabis cultivator located in the Algarve region of Portugal, is excited to announce an agreement with Canopy Growth Germany GmbH, a subsidiary of Canopy Growth Corporation, a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. This agreement marks a significant step in Gro-Vida’s efforts to meet the opportunity of the rapidly expanding medicinal cannabis market in Germany while aligning with Canopy Growth GmbH’s strategy for securing EU-based supply through an asset light model in addition to existing supply from the company’s Canadian GMP production platform.
“We are incredibly proud to be working with Canopy Growth Germany,” shares Mallory Bodnar, Managing Director at Gro-Vida. “It is a remarkable honor to have a global leader recognize the exceptional quality of cannabis produced here in Portugal. This is not only a testament to our hard work but points to the promising future of Portuguese-grown cannabis on the world stage.”
The supply agreement represents an exciting opportunity to drive growth for both companies, blending Gro-Vida’s cultivation expertise and EU-GMP production partnerships with Canopy Growth GmbH’s extensive network and in-market expertise. Under the terms of the supply agreement, Gro-Vida will cultivate a range of exclusive medicinal cannabis flower for Canopy Growth GmbH, with the products slated for release under the Tweed brand.
Tara Rozalowsky, Chief Growth Officer and President, International, Canopy Growth, highlights that this move is part of the company’s larger plans for international expansion: “Part of our global strategy is ensuring a diverse and high-quality supply chain, and Gro-Vida is an important piece of this strategy. Sourcing EU-GMP flower from Portugal, alongside our EU-GMP Canadian-grown cannabis flower, allows us to offer a versatile and competitive product portfolio in the German market while advancing our asset light strategy for growth.”
Products will be available via prescription and can be requested by patients nationwide in Germany from their healthcare practitioner beginning in calendar Q1 of 2025.
Leave a Reply